00
002720.KO Kukje Pharma Co Ltd
- Market cap
- KRW 70.4B
- P/E
- 14.3x
- P/B
- 0.72x
- ROE
- 7.7%
- Dividend yield
- 0.87%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 002720.KO undervalued?
Graham number002720.KO trades 32.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kukje Pharma Co Ltd fundamental analysis
No fundamental analysis for Kukje Pharma Co Ltd yet.
Kukje Pharma Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adre…
Full company profileKukje Pharma Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kukje Pharma Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 121B | 123B | 108B | 111B | 130B | 120B | 127B | 135B | 156B | 175B | 185B |
| Gross Profit | 53.8B | 51.5B | 48.8B | 53.0B | 64.8B | 54.5B | 63.3B | 67.2B | 82.5B | 93.6B | 101B |
| Operating Income | 3.97B | 2.56B | 3.29B | 5.57B | 6.04B | -1.68B | 5.27B | -1.99B | 6.70B | 6.18B | 8.20B |
| EBITDA | - | 5.58B | 6.47B | 4.24B | 9.87B | 4.01B | 10.2B | -1.04B | 11.0B | 10.6B | 13.8B |
| Net Income | 773M | 1.09B | 2.19B | -4.76B | 2.20B | -1.56B | 3.56B | -8.42B | 5.21B | 5.70B | 7.64B |
| EPS | - | 62 | 122 | -259 | 120 | -81 | 176 | -416 | 256 | 269 | 361 |
| Balance Sheet | |||||||||||
| Total Assets | 129B | 132B | 126B | 135B | 146B | 140B | 137B | 163B | 166B | 182B | 185B |
| Total Liabilities | 61.9B | 63.9B | 57.5B | 73.6B | 75.1B | 71.2B | 62.5B | 78.3B | 76.0B | 84.6B | 85.8B |
| Shareholders' Equity | 67.5B | 67.7B | 68.7B | 60.9B | 70.5B | 68.6B | 74.1B | 84.9B | 89.5B | 97.7B | 99.4B |
| Cash & Short-term Investments | 6.39B | 2.53B | 3.66B | 7.45B | 4.01B | 7.87B | 5.54B | 10.6B | 8.68B | 10.7B | 14.9B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.1B | 786M | 13.2B | 3.60B | 5.10B | 9.60B | 6.50B | 3.58B | 3.94B | 5.84B | 12.1B |
| Capital Expenditure | 2.69B | 2.61B | 3.03B | 5.89B | 11.6B | 1.89B | 1.26B | 1.05B | 2.99B | 3.87B | 2.81B |
| Free Cash Flow | - | -3.32B | 9.80B | -2.28B | -6.50B | 7.64B | 5.23B | 2.53B | 945M | 1.97B | 9.27B |
| Ratios | |||||||||||
| ROE | 1.1% | 1.6% | 3.2% | -7.8% | 3.1% | -2.3% | 4.8% | -9.9% | 5.8% | 5.8% | 7.7% |
| ROA | 0.6% | 0.8% | 1.7% | -3.5% | 1.5% | -1.1% | 2.6% | -5.2% | 3.1% | 3.1% | 4.1% |
| Net Profit Margin | 0.6% | 0.9% | 2.0% | -4.3% | 1.7% | -1.3% | 2.8% | -6.2% | 3.3% | 3.2% | 4.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kukje Pharma Co Ltd dividends
- Dividend yield
- 0.87%
- Forward dividend
- 30.00 KRW
- Payout ratio
- 10.7%
- Ex-dividend date
- Mar 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 611M | 29 | 10.7% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | KRW 515M | 28 | - |
| 2018 | KRW 165M | 9.16 | 7.5% |
| 2017 | KRW 158M | 8.93 | 14.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Mar 17, 2023.
Who owns Kukje Pharma Co Ltd
- Insiders 37.95%
- Institutions 0.06%
- Public & others 61.98%
- Shares outstanding 21.2M
- Free float 11.2M
Kukje Pharma Co Ltd company profile
- Company name
- Kukje Pharma Co Ltd
- Ticker
- 002720.KO
- ISIN
- KR7002720001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 266
- Fiscal year end
- December
- Address
- 96-8, Yatap-ro, Seongnam-si, South Korea
- Phone
- 82 3 1781 9081
- Website
- kukjepharm.co.kr
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, other ETC products, and other products. Kukje Pharma Co., Ltd. was founded in 1959 and is headquartered in Seongnam-si, South Korea.
Kukje Pharma Co Ltd management
9- Tae-hoon NamCEO, President & Director
- KiSeok YoonDeputy Director of Finance Department
- Sung-Gyu KimCOO & Director · born 1964
- Mr. Young Kwan KimCTO, MD & Director
- Hyunsuk ChungSenior Director of Human Resources & Administration Department
- GyeongGu JeongSenior Director of Public Affairs Team
- DongSeon KimDeputy Director of Marketing Department
- OhYong KwonDeputy MD of Sales Division
- BoSuk OhDeputy MD & CSO